Encompass Health Co. (NYSE:EHC) Shares Sold by Brevan Howard Capital Management LP

Brevan Howard Capital Management LP cut its holdings in shares of Encompass Health Co. (NYSE:EHC) by 40.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,742 shares of the company’s stock after selling 3,864 shares during the period. Brevan Howard Capital Management LP’s holdings in Encompass Health were worth $530,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. boosted its stake in shares of Encompass Health by 0.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 644,764 shares of the company’s stock worth $59,544,000 after acquiring an additional 4,345 shares in the last quarter. Merit Financial Group LLC purchased a new position in Encompass Health in the 4th quarter worth about $374,000. BI Asset Management Fondsmaeglerselskab A S purchased a new position in shares of Encompass Health in the fourth quarter worth approximately $4,160,000. MassMutual Private Wealth & Trust FSB raised its stake in Encompass Health by 87.8% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 293 shares of the company’s stock valued at $27,000 after purchasing an additional 137 shares during the period. Finally, US Bancorp DE lifted its stake in Encompass Health by 9.6% in the 4th quarter. US Bancorp DE now owns 1,380 shares of the company’s stock worth $127,000 after acquiring an additional 121 shares in the last quarter. 97.25% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Encompass Health news, EVP John Patrick Darby sold 10,000 shares of the stock in a transaction dated Tuesday, April 29th. The stock was sold at an average price of $114.79, for a total value of $1,147,900.00. Following the transaction, the executive vice president now owns 79,710 shares of the company’s stock, valued at approximately $9,149,910.90. This represents a 11.15 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Elissa Joy Charbonneau sold 4,279 shares of the business’s stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $116.61, for a total value of $498,974.19. Following the transaction, the insider now owns 11,958 shares of the company’s stock, valued at $1,394,422.38. The trade was a 26.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 19,321 shares of company stock worth $2,142,452 over the last three months. 2.00% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. StockNews.com lowered Encompass Health from a “buy” rating to a “hold” rating in a report on Saturday, May 3rd. KeyCorp increased their target price on shares of Encompass Health from $120.00 to $122.00 and gave the company an “overweight” rating in a research note on Friday, April 25th. Truist Financial reiterated a “buy” rating and set a $135.00 price target (up previously from $116.00) on shares of Encompass Health in a research note on Monday, April 28th. Barclays upped their price objective on Encompass Health from $118.00 to $129.00 and gave the company an “overweight” rating in a research note on Friday, April 25th. Finally, William Blair restated an “outperform” rating on shares of Encompass Health in a research note on Friday, February 7th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $120.86.

Encompass Health Stock Performance

Encompass Health stock opened at $116.45 on Friday. Encompass Health Co. has a 12-month low of $82.74 and a 12-month high of $118.27. The stock has a 50-day simple moving average of $103.44 and a 200 day simple moving average of $99.93. The company has a quick ratio of 1.04, a current ratio of 1.05 and a debt-to-equity ratio of 0.84. The stock has a market capitalization of $11.74 billion, a price-to-earnings ratio of 26.11, a P/E/G ratio of 2.31 and a beta of 0.91.

Encompass Health (NYSE:EHC) last released its quarterly earnings results on Thursday, April 24th. The company reported $1.37 EPS for the quarter, beating the consensus estimate of $1.19 by $0.18. Encompass Health had a net margin of 8.48% and a return on equity of 17.56%. The business had revenue of $1.46 billion for the quarter, compared to analysts’ expectations of $1.43 billion. During the same period in the prior year, the firm earned $1.12 earnings per share. Encompass Health’s revenue was up 10.6% compared to the same quarter last year. On average, research analysts anticipate that Encompass Health Co. will post 4.8 earnings per share for the current fiscal year.

Encompass Health Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Tuesday, July 1st will be paid a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a dividend yield of 0.58%. The ex-dividend date of this dividend is Tuesday, July 1st. Encompass Health’s dividend payout ratio (DPR) is presently 14.05%.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.